Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in the interest of Mr. D J Phelan in Ordinary share ADRs. This change resulted from the re-investment of the dividend paid to shareholders on January 7, 2010, at a price of $41.48 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 12, 2010.
- Subject: Mr. D J Phelan.
- Transaction Type: Increase in interest in Ordinary share ADRs via dividend re-investment.
- Price per ADR: $41.48.
- Dividend Payment Date: January 7, 2010.